Screening strategy versus drug efficacy: Revisiting the evidence for vaginal progesterone in short cervix
Jeremy Boujenah, Patrick Rozenberg · 2026
Read Screening strategy versus drug efficacy: Revisiting the evidence for vaginal progesterone in short cervix by Jeremy Boujenah, Patrick Rozenberg (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427669.txt.
Description
Boujenah and Rozenberg wrote in 2026 to dispute a review's verdict that evidence is too weak to back universal cervix screening with vaginal progesterone to prevent preterm birth. Their charge is that the review blends two separate questions: whether screening whole populations helps, and whether the drug works in women already found to have a short cervix.
The trials behind the verdict compared screening against no screening, and fewer than three in a hundred women in them ever received the drug, which dilutes any effect toward zero. Trials that gave progesterone to women with a short cervix did show benefit. The letter also notes that screening trials used looser length cut-offs, enrolling lower-risk women. Weighing biology, pooled patient-level analyses, and the drug's low risk and cost, the authors argue for offering the strategy now.
Catalog record
| CREATOR | Jeremy Boujenah, Patrick Rozenberg |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 4 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |